Uncovering molecular underpinnings could lead to new, genetically targeted therapies
THURSDAY, May 8 (HealthDay News) -- New information about the molecular mechanisms that cause cardiac arrhythmia (irregular heartbeat) and how it triggers sudden cardiac death has been uncovered by Rhode Island Hospital researchers.
They said their findings could lead to the development of new, genetically targeted therapies to treat and prevent fatal arrhythmias. The study was published online Thursday in The Journal of Clinical Investigation.
"We are still struggling to understand why arrhythmia causes sudden cardiac death in some patients, but not others, and what underlying molecular mechanisms or abnormalities may be at play," study senior author Dr. Gideon Koren, director of the cardiovascular research center at Rhode Island Hospital and a professor of medicine at Brown University's medical school, said in a prepared statement.
He and his team developed animal models of long QT syndrome (LQTS) -- a disorder of the heart's electrical system that causes fast, chaotic heartbeats -- to study the various mechanisms that cause arrhythmia. The animal models included the two most common genetic forms of LQTS in humans -- LQT1 and LQT2.
In both forms, faulty genes lead to production of abnormal ion channels, the proteins responsible for moving potassium in and out of heart cells so they can contract. In LQT1, the mutation is in the KvLQT1 gene, while in LQT2, the mutation is in the HERG gene.
The animals with LQT2 exhibited spontaneous arrhythmias, and some of them died suddenly, while there was no spontaneous arrhythmia or sudden death among the animals with LQT1.
The researchers believe that the electrical cause for the deadly arrhythmias in the LQT2 group is increased spatial dispersion of repolarization across the front of the outside layers of cardiac muscle. The LQT1 group did not have incre
All rights reserved